News stories about Ionis Pharmaceuticals (NASDAQ:IONS) have trended somewhat positive on Tuesday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.2466853191447 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
Several equities analysts have recently weighed in on IONS shares. TheStreet lowered Ionis Pharmaceuticals from a “c” rating to a “d+” rating in a research note on Tuesday, February 27th. ValuEngine lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd. Zacks Investment Research lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 10th. BidaskClub raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 9th. Finally, BMO Capital Markets lifted their price objective on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company’s stock. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $52.15.
Shares of NASDAQ:IONS opened at $43.47 on Tuesday. The stock has a market cap of $5,471.78, a P/E ratio of 543.38 and a beta of 2.50. The company has a current ratio of 5.20, a quick ratio of 5.15 and a debt-to-equity ratio of 1.45. Ionis Pharmaceuticals has a one year low of $40.33 and a one year high of $65.51.
Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.10. The business had revenue of $172.00 million for the quarter, compared to the consensus estimate of $126.38 million. Ionis Pharmaceuticals had a negative return on equity of 1.94% and a negative net margin of 1.18%. The company’s revenue was up 7.5% on a year-over-year basis. During the same period last year, the business posted $0.33 EPS. equities analysts forecast that Ionis Pharmaceuticals will post -0.13 earnings per share for the current year.
In other Ionis Pharmaceuticals news, SVP Patrick R. O’neil sold 645 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Thursday, January 25th. The stock was sold at an average price of $55.00, for a total transaction of $35,475.00. Following the sale, the senior vice president now directly owns 15,097 shares in the company, valued at approximately $830,335. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $52.86, for a total value of $158,580.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,500 shares of company stock worth $2,017,410. Company insiders own 2.13% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/17/ionis-pharmaceuticals-ions-earns-news-sentiment-rating-of-0-08.html.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.